Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation

Intensive Care Medicine

Volumn 36, Issue 7, 2010, Pages 1273-1274

  Lemaitre, Florian ^a   Luyt, Charles Edouard ^a,b   Roullet Renoleau, François ^a   Nieszkowska, Ania ^a,b   Zahr, Noël ^a   Fernandez, Christine ^a,c   Farinotti, Robert ^a,c   Combes, Alain ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ANTIVIRUS AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIMICROBIAL THERAPY; ANURIA; BREATHING RATE; CONTINUOUS HEMODIAFILTRATION; COUGHING; DRUG ACCUMULATION; DRUG HALF LIFE; EXTRACORPOREAL OXYGENATION; HUMAN; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; LETTER; LIQUID CHROMATOGRAPHY; LUNG LAVAGE; OXYGEN SATURATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; THORAX PAIN; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CASE REPORT; FEMALE; HEMOFILTRATION; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; METABOLISM; RESPIRATORY DISTRESS SYNDROME, ADULT; VIROLOGY; YOUNG ADULT;

ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEMOFILTRATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; RESPIRATORY DISTRESS SYNDROME, ADULT; YOUNG ADULT;

EID: 77954382508     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-010-1882-9     Document Type: Letter

References (5)

1. LM Napolitano PK Park KC Sihler T Papadimos C Chenoweth S Cinti C Zalewski R Sharangpani P Somsel E Wells AM Fry AE Fiore JM Villanueva S Lindstrom TM Uyeki Center for Disease Control 2009 Intensive-care patients with severe novel influenza A (H1N1) virus infection MMWR Morb Mortal Wkly Rep 58 749 752
2. MS Firstenberg D Blais LB Louis KB Stevenson B Sun JE Mangino 2009 Extracorporeal membrane oxygenation for pandemic (H1N1) 2009 Emerg Infect Dis 15 2059 2060 10.3201/eid1512.091434 19961702
3. S Ruiz E Papy D Da Silva P Nataf L Massias M Wolff L Bouadma 2009 Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation Intensive Care Med 35 183 184 10.1007/s00134-008-1269-3 18795256
4. R Robson A Buttimore K Lynn M Brewster P Ward 2006 The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis Nephrol Dial Transplant 21 2556 2562 10.1093/ndt/gfl267 1:CAS:528:DC%2BD28XhtVWlt7%2FM 16799169
5. Dutkowski R, Smith JR, Davies BE (2010) Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2009.12.023